- Home
- STTK vs FLL Comparison
STTK vs FLL Comparison
Compare STTK & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FLL
- Stock Information
- Founded
- STTK 2016
- FLL 1987
- Country
- STTK United States
- FLL United States
- Employees
- STTK N/A
- FLL N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- STTK Health Care
- FLL Consumer Discretionary
- Exchange
- STTK Nasdaq
- FLL Nasdaq
- Market Cap
- STTK 83.8M
- FLL 133.3M
- IPO Year
- STTK 2020
- FLL 1993
- Fundamental
- Price
- STTK $2.14
- FLL $3.46
- Analyst Decision
- STTK Hold
- FLL Buy
- Analyst Count
- STTK 6
- FLL 5
- Target Price
- STTK $2.67
- FLL $5.80
- AVG Volume (30 Days)
- STTK 1.5M
- FLL 129.7K
- Earning Date
- STTK 11-13-2025
- FLL 11-05-2025
- Dividend Yield
- STTK N/A
- FLL N/A
- EPS Growth
- STTK N/A
- FLL N/A
- EPS
- STTK N/A
- FLL N/A
- Revenue
- STTK $2,997,000.00
- FLL $297,653,000.00
- Revenue This Year
- STTK N/A
- FLL $4.96
- Revenue Next Year
- STTK N/A
- FLL $8.15
- P/E Ratio
- STTK N/A
- FLL N/A
- Revenue Growth
- STTK N/A
- FLL 8.24
- 52 Week Low
- STTK $0.69
- FLL $2.86
- 52 Week High
- STTK $3.95
- FLL $5.59
- Technical
- Relative Strength Index (RSI)
- STTK 58.93
- FLL 43.43
- Support Level
- STTK N/A
- FLL $3.29
- Resistance Level
- STTK $2.01
- FLL $3.55
- Average True Range (ATR)
- STTK 0.21
- FLL 0.17
- MACD
- STTK 0.01
- FLL 0.02
- Stochastic Oscillator
- STTK 99.53
- FLL 30.91
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.